Pagibaximab

Pagibaximab is a monoclonal antibody specifically designed for the prevention of Staphylococcus aureus infections in neonates. It is a type of biopharmaceutical that was developed by Biosynexus Incorporated and GlaxoSmithKline.

Mechanism of Action[edit | edit source]

Pagibaximab works by binding to the lipoteichoic acid (LTA) present in the cell wall of Staphylococcus aureus. This binding action inhibits the bacteria's ability to adhere to the host's cells, thereby preventing infection.

Clinical Trials[edit | edit source]

Pagibaximab has undergone several clinical trials to evaluate its safety and efficacy. In Phase II trials, it was found to be safe and well-tolerated in neonates at risk for Staphylococcus aureus infections. However, the drug did not meet the primary endpoint in Phase III trials, leading to the discontinuation of its development.

Potential Uses[edit | edit source]

Despite the discontinuation of its development, Pagibaximab has potential uses in the prevention of Staphylococcus aureus infections in other high-risk populations, such as patients undergoing hemodialysis or those with compromised immune systems.